Nasopharyngeal Carcinoma Treated With Reduced Volume Intensity Modulated Radiation Therapy:10-Year Outcome and Late Toxicity, Quality of Life - Trial NCT06136962
Access comprehensive clinical trial information for NCT06136962 through Pure Global AI's free database. This phase not specified trial is sponsored by Fujian Cancer Hospital and is currently Not yet recruiting. The study focuses on Nasopharyngeal Carcinoma. Target enrollment is 500 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Observational
Sponsor & Location
Fujian Cancer Hospital
Timeline & Enrollment
N/A
Dec 01, 2023
Dec 01, 2024
Primary Outcome
Overall survival
Summary
Nasopharyngeal carcinoma (NPC) is a type of head and neck cancer. The last three decades of
 research in head and neck radiation oncology have largely focused on improvements in
 survival, which have mostly come at the cost of long term toxicity for surviving
 patients.This is an observational study that is being done to evaluate the long-term
 efficacy, learn about the toxicity and quality of life that survivors of nasopharyngeal
 carcinoma may have following treated with reduced volume intensity modulated radiation
 therapy.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06136962
Non-Device Trial